IGM Biosciences Inc (IGMS)

Sector:
HEALTH CARE
Industry:
BIOTECHNOLOGY & LIFE SCIENCES
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Fred M. Schwarzer
Employees:
190
325 E MIDDLEFIELD ROAD, MOUNTAIN VIEW, CA 94043
650-965-7873

IGM Biosciences, Inc. develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company's lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin's lymphoma.

Data derived from most recent annual or quarterly report
Market Cap 327.049 Million Shares Outstanding41.19 Million Avg 30-day Volume 248.634 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-1.33
Price to Revenue0.0 Debt to Equity0.0 EBITDA-248.898 Million
Price to Book Value1.6105 Operating Margin0.0 Enterprise Value28.973 Million
Current Ratio9.069 EPS Growth0.081 Quick Ratio8.733
1 Yr BETA 1.8755 52-week High/Low 28.2 / 6.45 Profit Margin0.0
Operating Cash Flow Growth-6824.6681 Free Cash Flow to Firm (FCFF) TTM -183.438 Million Free Cash Flow to Equity (FCFE) TTM-187.107 Million
Altman Z-Score-1.7225
Earnings Report2023-11-02
View SEC Filings from IGMS instead.

View recent insider trading info

IGM Biosciences Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding IGMS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding IGMS

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-07-05 by LOBERG MICHAEL D
  • 4: filed on 2023-07-05 by GAUTHIER GEORGE
  • 4: filed on 2023-07-05 by TOPSOE CHRISTINA TENG
  • 4: filed on 2023-07-05 by BEHRENS M KATHLEEN
  • 4: filed on 2023-07-03 by LEE MICHAEL STEWART
  • 4: filed on 2023-07-03 by REDMILE GROUP, LLC
  • 4: filed on 2023-07-03 by TOPSOE JAKOB HALDOR
  • 4: filed on 2023-06-28 by REDMILE GROUP, LLC
  • 4: filed on 2023-06-28 by TOPSOE JAKOB HALDOR
  • 4: filed on 2023-06-28 by TOPSOE CHRISTINA TENG

    • Events (8k)

  • 8-K: filed on 2023-08-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-27:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-23:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 3.02: Unregistered Sales of Equity Securities
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-21:
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-12:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-30:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-21:
    Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
  • 8-K: filed on 2023-03-10:
    Item 7.01: Regulation FD Disclosure
  • 8-K: filed on 2023-01-06:
    Item 2.02: Results of Operations and Financial Condition
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-11-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    GAUTHIER GEORGE CHIEF COMMERCIAL OFFICER

    • Officer
    		 40,017 2023-07-03 7

    BAKER BROS. ADVISORS LP

    667, L.P.

    BAKER FELIX

    BAKER JULIAN

    BAKER BROS. ADVISORS (GP) LLC

    BAKER BROTHERS LIFE SCIENCES LP

    • Director
    		 3,170,420 2023-06-30 4

    BEHRENS M KATHLEEN

    • Director
    		 395,681 2023-06-30 7

    LOBERG MICHAEL D

    • Director
    		 81,790 2023-06-30 5

    LEE MICHAEL STEWART

    • Director
    		 3,136 2023-06-30 5

    TOPSOE CHRISTINA TENG

    • Director
    • 10% Owner
    		 10,449,807 2023-06-30 6

    REDMILE GROUP, LLC

    GREEN JEREMY

    • Director
    		 2,974,678 2023-06-29 7

    TOPSOE JAKOB HALDOR

    • Director
    • 10% Owner
    		 10,560,844 2023-06-29 6

    TOPSOE HOLDING A/S

    • 10% Owner
    		 0 2023-06-26 1

    TAKIMOTO CHRIS H CHIEF MEDICAL OFFICER

    • Officer
    		 54,742 2023-05-23 5

    DECKER LISA LYNN CHIEF BUSINESS OFFICER

    • Officer
    		 41,181 2023-05-23 6

    TAHIR MISBAH CHIEF FINANCIAL OFFICER

    • Officer
    		 50,711 2023-05-23 5

    SCHWARZER FRED CEO AND PRESIDENT

    • Officer
    • Director
    		 318,479 2023-05-23 5

    KEYT BRUCE CHIEF SCIENTIFIC OFFICER

    • Officer
    		 139,071 2023-05-23 9

    HAMBLETON JULIE

    • Director
    		 0 2023-04-04 1

    STROHL WILLIAM

    • Director
    		 0 2023-04-04 1

    WEBER STEVEN PRINCIPAL ACCOUNTING OFFICER

    • Officer
    		 8,750 2023-04-04 1

    CHEN DANIEL SHINYU CHIEF MEDICAL OFFICER

    • Officer
    		 572,319 2021-07-01 0

    NEU KELVIN

    • Director
    		 0 2019-09-17 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    IGM BIOSCIENCES INC IGMS 2023-09-27 22:15:05 UTC 4.5337 0.7863 20000
    IGM BIOSCIENCES INC IGMS 2023-09-27 21:45:03 UTC 4.5337 0.7863 20000
    IGM BIOSCIENCES INC IGMS 2023-09-27 21:15:04 UTC 4.5337 0.7863 20000
    IGM BIOSCIENCES INC IGMS 2023-09-27 20:45:04 UTC 4.5337 0.7863 20000
    IGM BIOSCIENCES INC IGMS 2023-09-27 20:15:05 UTC 4.5337 0.7863 20000
    IGM BIOSCIENCES INC IGMS 2023-09-27 19:45:03 UTC 4.5337 0.7863 20000
    IGM BIOSCIENCES INC IGMS 2023-09-27 19:15:04 UTC 4.5337 0.7863 20000
    IGM BIOSCIENCES INC IGMS 2023-09-27 18:45:04 UTC 4.4708 0.8492 20000
    IGM BIOSCIENCES INC IGMS 2023-09-27 18:15:04 UTC 4.4708 0.8492 20000
    IGM BIOSCIENCES INC IGMS 2023-09-27 17:45:03 UTC 0.0 0.0 20000
    IGM BIOSCIENCES INC IGMS 2023-09-27 17:15:03 UTC 0.0 0.0 35000
    IGM BIOSCIENCES INC IGMS 2023-09-27 16:45:04 UTC 4.4708 0.8492 35000
    IGM BIOSCIENCES INC IGMS 2023-09-27 16:15:05 UTC 4.4708 0.8492 35000
    IGM BIOSCIENCES INC IGMS 2023-09-27 15:45:04 UTC 4.479 0.841 35000
    IGM BIOSCIENCES INC IGMS 2023-09-27 15:15:03 UTC 4.479 0.841 35000
    IGM BIOSCIENCES INC IGMS 2023-09-27 14:45:03 UTC 4.479 0.841 35000
    IGM BIOSCIENCES INC IGMS 2023-09-27 14:15:03 UTC 4.479 0.841 35000
    IGM BIOSCIENCES INC IGMS 2023-09-27 13:45:03 UTC 4.5358 0.7842 35000
    IGM BIOSCIENCES INC IGMS 2023-09-27 13:15:05 UTC 4.5358 0.7842 35000
    IGM BIOSCIENCES INC IGMS 2023-09-27 12:45:05 UTC 4.5358 0.7842 25000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin
    Weiss Strategic Interval Fund- Weiss Strategic Interval Fund IGMS -3561.0 shares, $-80977.14 2022-09-30 N-PORT
    INVESTMENT MANAGERS SERIES TRUST- 361 Domestic Long/Short Equity Fund IGMS -205.0 shares, $-4100.0 2022-10-31 N-PORT
    Series Portfolios Trust- Weiss Alternative Multi-Strategy Fund IGMS -2002.0 shares, $-21681.66 2023-04-30 N-PORT
    Blackstone Alternative Investment Funds- Blackstone Alternative Multi-Strategy Fund IGMS -200.0 shares, $-1846.0 2023-06-30 N-PORT
    ALLSPRING FUNDS TRUST- Allspring U.S. Long/Short Equity Fund IGMS -1250.0 shares, $-13300.0 2023-07-31 N-PORT

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments